Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102482 | 0.88 | NPSR1 (0.46) | HSD17B10ALDH1A1NPSR1TSHRUSP2 | |
| SCHEMBL5109037 | 0.84 | HSD17B10 (0.40) | HSD17B10ALDH1A1TSHRTGFBR1KDM4E | |
| SCHEMBL5106704 | 0.84 | EGFR (0.38) | HSD17B10ALDH1A1NPSR1TSHRUSP2 | |
| SCHEMBL4491044 | 0.84 | CUL4A (0.36) | HSD17B10ALDH1A1NPSR1TGFBR1KDM4E | |
| SCHEMBL5115809 | 0.81 | HPGDS (0.37) | ALDH1A1NPSR1TSHRUSP2TGFBR1 | |
| SCHEMBL5108953 | 0.81 | LMNA (0.37) | HSD17B10ALDH1A1NPSR1TSHRUSP2 | |
| SCHEMBL5114296 | 0.79 | LMNA (0.48) | ALDH1A1NPSR1TSHRUSP2TGFBR1 | |
| SCHEMBL4502684 | 0.79 | CCNA2 (0.35) | HSD17B10ALDH1A1NPSR1TSHRTGFBR1 | |
| SCHEMBL5115683 | 0.78 | CCNA2 (0.36) | ALDH1A1TGFBR1LMNACCNA2CDK2 | |
| SCHEMBL5114414 | 0.78 | CCNA2 (0.43) | HSD17B10ALDH1A1NPSR1TSHRTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | claimed |
| US-20050090521-A1 | HCV inhibitors and methods of using them | RIGEL PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | claimed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | HSD17B10 1164/4885ALDH1A1 874/4885NPSR1 3998/4885 |
| US-20050090521-A1 | HCV inhibitors and methods of using them | HAVCR2, GLS2, EIF2AK2 | HSD17B10 1164/4885ALDH1A1 874/4885NPSR1 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.